Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy
- PMID: 21604987
- DOI: 10.1586/erv.11.14
Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy
Abstract
The polysaccharide-encapsulated bacteria, Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae are important causes of invasive bacterial infection in childhood, accounting for most of the cases of bacterial pneumonia and meningitis worldwide. Protein-polysaccharide conjugate vaccines have been developed over the last 20 years and have proven very effective in controlling these infections. Although studies have consistently shown that herd immunity is critical for population protection, long-term individual protection against polysaccharide-encapsulated bacteria appears to depend on persisting antibody and, perhaps to a lesser extent, immunological memory. However, some studies have reported that the concentration of serum antibody and vaccine effectiveness are not sustained after infant immunization, despite persistence of immunological memory. In this article, we detail the mechanisms of protection against invasion by encapsulated bacteria, describe the age-dependent B-cell and antibody responses to protein-polysaccharide conjugate vaccines and propose strategies to guarantee protection during periods of increased disease burden.
Similar articles
-
Immune responses to polysaccharides: lessons from humans and mice.Vaccine. 2008 Jan 17;26(3):292-300. doi: 10.1016/j.vaccine.2007.11.042. Epub 2007 Dec 3. Vaccine. 2008. PMID: 18160186 Review.
-
Conjugate vaccines--a breakthrough in vaccine development.Southeast Asian J Trop Med Public Health. 2003 Jun;34(2):249-53. Southeast Asian J Trop Med Public Health. 2003. PMID: 12971544 Review.
-
Challenges in immunisation against bacterial infection in children.Early Hum Dev. 2010 Nov;86(11):695-701. doi: 10.1016/j.earlhumdev.2010.08.010. Epub 2010 Sep 19. Early Hum Dev. 2010. PMID: 20851537
-
Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.Nat Rev Immunol. 2009 Mar;9(3):213-20. doi: 10.1038/nri2494. Nat Rev Immunol. 2009. PMID: 19214194
-
Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.Pediatr Infect Dis J. 2009 Apr;28(4 Suppl):S77-88. doi: 10.1097/INF.0b013e318199f609. Pediatr Infect Dis J. 2009. PMID: 19325450 Clinical Trial.
Cited by
-
Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines.Front Mol Biosci. 2023 May 16;10:1201693. doi: 10.3389/fmolb.2023.1201693. eCollection 2023. Front Mol Biosci. 2023. PMID: 37261327 Free PMC article. Review.
-
Immune response to vaccine adjuvants during the first year of life.Vaccine. 2013 May 17;31(21):2500-5. doi: 10.1016/j.vaccine.2012.10.016. Epub 2012 Oct 18. Vaccine. 2013. PMID: 23085363 Free PMC article. Review.
-
Epidemiology and Control of Meningococcal Disease in Canada: A Long, Complex, and Unfinished Story.Can J Infect Dis Med Microbiol. 2019 Nov 25;2019:8901847. doi: 10.1155/2019/8901847. eCollection 2019. Can J Infect Dis Med Microbiol. 2019. PMID: 31885753 Free PMC article. Review.
-
Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine.PLoS One. 2017 Aug 24;12(8):e0183427. doi: 10.1371/journal.pone.0183427. eCollection 2017. PLoS One. 2017. PMID: 28837693 Free PMC article.
-
Differential B-cell memory around the 11-month booster in children vaccinated with a 10- or 13-valent pneumococcal conjugate vaccine.Clin Infect Dis. 2015 Aug 1;61(3):342-9. doi: 10.1093/cid/civ274. Epub 2015 Apr 1. Clin Infect Dis. 2015. PMID: 25838290 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical